Piramal Healthcare expands Scottish plant

Invests 2 mn pounds; expansion to yield additional 2-5 mn pounds in revenue over 5 years

Piramal Healthcare has invested two million pounds (about Rs 20 crore) to expand its manufacturing plant in Scotland. The plant manufactures anti-cancer drugs (antibody drug conjugates) for export. This new investment into Scotland will yield additional revenue of 3-5 million pounds (about Rs 30-50 crore) over five years to Piramal Healthcare's revenue.

Piramal Healthcare Site Lead, Mark Wright, said: "Piramal Healthcare UK has been growing its operations in Grangemouth in Scotland since 2005 and currently employs around 140 people in predominantly highly skilled positions. We aim to scale up this facility in the next 5 years to maintain its position as a global leader in the production of antibody drug conjugates."

Piramal Healthcare has manufacturing plants in India, US, Canada and Scotland and contributes to about 60 percent of the Rs 5,000 crore group revenue in FY15.